We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
How to apply for a clinical trial including eligibility, phases, model IMPDs, costs and how to make changes to your application.
Opportunity to license Dstl technology: using statistical techniques and machine learning to improve the efficiency of identifying potential data of interest.
A new pathway supporting innovative approaches to the safe, timely and efficient development of medicines to improve patient access.
We’re working to help people securely prove who they are without having to rely on physical documents.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine etrasimod (Velsipity) to treat people with moderately to severely active ulcerative colitis.
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices, and information about the publication of two recent Device Safety Information pages. The article also includes information on a recent National Patient Safety Alert...
Following MHRA approval of a clinical trial, early breast cancer patients on endocrine-based therapy can benefit from a study with camizestrant.
The Independent Monitoring Authority for the Citizens’ Rights Agreements (IMA) will work to protect the rights of EU and EEA EFTA (Iceland, Liechtenstein and Norway) citizens in the UK and Gibraltar. IMA is an executive non-departmental public body, sponsored by...
Patients with severe alopecia areata (patchy hair loss) could access a new medicine to help treat their condition.
We provide independent panels that review suitability to adopt or foster and other decisions made by adoption and fostering providers. IRM works with the Department for Education .
For the first time, patients with certain types of advanced or recurrent endometrial cancer could access a treatment shown to slow its progression
The eMIT provides information about prices and usage for generic drugs and pharmaceutical products.
Armilla Verified is Armilla’s third-party verification of AI-powered products. It empowers AI vendors and enterprises alike to assure the quality and reliability of their AI solutions.
Case study from ISACA.
A series of indicators to inform safer prescribing practice to help pharmacists, clinicians and patients review prescribed medication and prevent harm.
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).